



Clinical trial results:

A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE)

Summary

EudraCT number	2011-005672-42
Trial protocol	GB
Global end of trial date	28 January 2019

Results information

Result version number	v2 (current)
This version publication date	07 February 2020
First version publication date	03 July 2019
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	115471
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	980 Great West Road, Brentford, Middlesex, United Kingdom,
Public contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 July 2019
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	28 January 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

- To evaluate the efficacy of belimumab in adult SLE participants of self-identified black race.
- To evaluate the safety and tolerability of belimumab in adult SLE participants of self-identified black race.

Protection of trial subjects:

Participants remained under clinical supervision for 3 hours after completion of the first 2 infusions.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	19 February 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United States: 248
Country: Number of subjects enrolled	Brazil: 178
Country: Number of subjects enrolled	Colombia: 42
Country: Number of subjects enrolled	South Africa: 19
Country: Number of subjects enrolled	United Kingdom: 12
Country: Number of subjects enrolled	France: 4
Worldwide total number of subjects	503
EEA total number of subjects	16

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	495

From 65 to 84 years	8
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

This study evaluated the efficacy and safety of belimumab compared with placebo in adult participants with Systemic Lupus Erythematosus (SLE). This was a multicenter study conducted at United States (88 centers), United Kingdom (6), South Africa (5), France (4), Columbia (6) and Brazil (18).

Pre-assignment

Screening details:

A total of 503 participants were randomized of which 496 received at-least one dose of study medication during double-blinded phase (7 participants were randomized but not treated as they were randomized in error). A total of 359 out of 373 participants who completed double-blinded phase opted to continue optional open-label (OL) extension phase.

Period 1

Period 1 title	Double-blinded (Up to Week 52)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo to Belimumab 10 mg/kg

Arm description:

In double-blinded (DB) phase, participants received matching placebo to belimumab administered as intravenous (IV) infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 milligram per kilogram (mg/kg) administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.

Arm type	Experimental
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Placebo was supplied in a 20 milliliters (mL) vial and prepared as a sterile and lyophilized product. Upon reconstitution with 4.8 mL sterile water for injection (SWFI), each vial contained 0.16 milligrams (mg)/milliliter (mL) citric acid, 2.7 mg/mL sodium citrate, 80 mg/mL sucrose, 0.4 mg/mL polysorbate 80, potential of hydrogen ions (pH) 6.5. Each lyophilized vial was for single use.

Arm title	Belimumab 10 mg/kg to Belimumab 10 mg/kg
------------------	--

Arm description:

In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.

Arm type	Experimental
Investigational medicinal product name	Belimumab 10 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Belimumab was supplied in a 20 mL vial containing 400 mg belimumab as a sterile, lyophilized product. Upon reconstitution with SWFI, each vial contained 80 mg/mL belimumab in 0.16 mg/mL citric acid, 2.7 mg/mL sodium citrate, 80 mg/mL sucrose, 0.4 mg/mL polysorbate 80, pH 6.5. Each lyophilized vial was

for single use.

Number of subjects in period 1^[1]	Placebo to Belimumab 10 mg/kg	Belimumab 10 mg/kg to Belimumab 10 mg/kg
Started	165	331
Completed	121	252
Not completed	44	79
Adverse event, serious fatal	-	1
Physician decision	9	12
Consent withdrawn by subject	10	14
Site Closed	3	5
Adverse event, non-fatal	10	18
Lost to follow-up	1	8
Protocol deviation	2	6
Lack of efficacy	9	15

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: A total of 503 participants were randomized of which 496 received at-least one dose of study medication during double-blinded phase (7 participants were randomized but not treated as they were randomized in error).

Period 2

Period 2 title	Open-label (Week 52 to Week 76)
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo to Belimumab 10 mg/kg

Arm description:

In double-blinded (DB) phase, participants received matching placebo to belimumab administered as intravenous (IV) infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 milligram per kilogram (mg/kg) administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.

Arm type	Experimental
Investigational medicinal product name	Belimumab 10 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Belimumab was supplied in a 20 mL vial containing 400 mg belimumab as a sterile, lyophilized product. Upon reconstitution with SWFI, each vial contained 80 mg/mL belimumab in 0.16 mg/mL citric acid, 2.7 mg/mL sodium citrate, 80 mg/mL sucrose, 0.4 mg/mL polysorbate 80, pH 6.5. Each lyophilized vial was for single use.

Arm title	Belimumab 10 mg/kg to Belimumab 10 mg/kg
------------------	--

Arm description:

In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.

Arm type	Experimental
Investigational medicinal product name	Belimumab 10 mg/kg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Belimumab was supplied in a 20 mL vial containing 400 mg belimumab as a sterile, lyophilized product. Upon reconstitution with SWFI, each vial contained 80 mg/mL belimumab in 0.16 mg/mL citric acid, 2.7 mg/mL sodium citrate, 80 mg/mL sucrose, 0.4 mg/mL polysorbate 80, pH 6.5. Each lyophilized vial was for single use.

Number of subjects in period 2^[2]	Placebo to Belimumab 10 mg/kg	Belimumab 10 mg/kg to Belimumab 10 mg/kg
Started	117	242
Completed	107	220
Not completed	10	22
Consent withdrawn by subject	5	2
Physician decision	1	4
Site Closed	2	8
Adverse event, non-fatal	1	-
Lost to follow-up	1	4
Protocol deviation	-	2
Lack of efficacy	-	2

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: A total of 503 participants were randomized of which 496 received at-least one dose of study medication during double-blinded phase (7 participants were randomized but not treated as they were randomized in error).

Baseline characteristics

Reporting groups

Reporting group title	Placebo to Belimumab 10 mg/kg
-----------------------	-------------------------------

Reporting group description:

In double-blinded (DB) phase, participants received matching placebo to belimumab administered as intravenous (IV) infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 milligram per kilogram (mg/kg) administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.

Reporting group title	Belimumab 10 mg/kg to Belimumab 10 mg/kg
-----------------------	--

Reporting group description:

In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.

Reporting group values	Placebo to Belimumab 10 mg/kg	Belimumab 10 mg/kg to Belimumab 10 mg/kg	Total
Number of subjects	165	331	496
Age categorical Units: Subjects			
Total Participants	165	331	496
Age Continuous Units: Years			
arithmetic mean	39.5	38.7	
standard deviation	± 12.06	± 11.00	-
Sex: Female, Male Units: Participants			
Female	158	322	480
Male	7	9	16
Race/Ethnicity, Customized Units: Subjects			
Black or African American	165	331	496

End points

End points reporting groups

Reporting group title	Placebo to Belimumab 10 mg/kg
Reporting group description: In double-blinded (DB) phase, participants received matching placebo to belimumab administered as intravenous (IV) infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 milligram per kilogram (mg/kg) administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Reporting group title	Belimumab 10 mg/kg to Belimumab 10 mg/kg
Reporting group description: In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Reporting group title	Placebo to Belimumab 10 mg/kg
Reporting group description: In double-blinded (DB) phase, participants received matching placebo to belimumab administered as intravenous (IV) infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 milligram per kilogram (mg/kg) administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Reporting group title	Belimumab 10 mg/kg to Belimumab 10 mg/kg
Reporting group description: In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks. In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Placebo (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In DB phase, participants received matching placebo to belimumab administered as IV infusion plus standard of care through 52 weeks.	
Subject analysis set title	Belimumab 10 mg/kg (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks.	
Subject analysis set title	Placebo to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Placebo to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days through Week 52 to Week 76.	
Subject analysis set title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	

Subject analysis set title	Placebo to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Placebo to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days through Week 52 to Week 76.	
Subject analysis set title	Belimumab 10 mg/kg (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks.	
Subject analysis set title	Placebo to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Placebo (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
In DB phase, participants received matching placebo to belimumab administered as IV infusion plus standard of care through 52 weeks.	

Subject analysis set title	Belimumab 10 mg/kg (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks.	
Subject analysis set title	Placebo to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76.	
Subject analysis set title	Placebo (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In DB phase, participants received matching placebo to belimumab administered as IV infusion plus standard of care through 52 weeks.	
Subject analysis set title	Belimumab 10 mg/kg (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks.	
Subject analysis set title	Placebo (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In DB phase, participants received matching placebo to belimumab administered as IV infusion plus standard of care through 52 weeks.	
Subject analysis set title	Belimumab 10 mg/kg (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks.	
Subject analysis set title	Belimumab 10 mg/kg (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks.	
Subject analysis set title	Belimumab 10 mg/kg (DB Phase)
Subject analysis set type	Sub-group analysis
Subject analysis set description: In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks.	

Primary: Percentage of participants achieving a Systemic Lupus Erythematosus Responder Index (SRI) response rate with the modified Systemic Lupus Erythematosus disease activity index- 2K (SLEDAI-2K) scoring for proteinuria at Week 52 [DB Phase]

End point title	Percentage of participants achieving a Systemic Lupus Erythematosus Responder Index (SRI) response rate with the modified Systemic Lupus Erythematosus disease activity index- 2K (SLEDAI-2K) scoring for proteinuria at Week 52 [DB Phase]
-----------------	---

End point description:

SRI response is defined as ≥ 4 point reduction, from Baseline in safety of estrogen in Lupus National Assessment (SELENA) SLEDAI [SS] score (with modified SLEDAI-2K scoring for proteinuria [PU]), no worsening (increase of < 0.30 points from Baseline) in Physician's Global Assessment (PGA) and no new British Isles Lupus Assessment Group of SLE clinics (BILAG) A organ domain score [ODS] or 2 new BILAG B ODS compared with Baseline. Analysis performed for comparison between belimumab and placebo with covariates treatment group, Baseline SS score, Baseline complement levels and region. The Modified Intention-To-Treat (mITT) population comprised of safety population excluding participants who had any assessment at 3 sites (202196, 202513 or 107286). One participant in the mITT

population Belimumab 10 mg/kg arm did not have a screening or Baseline PGA assessment; therefore, this participant did not contribute to the SRI/component analysis.

End point type	Primary
End point timeframe:	
Week 52	

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	149 ^[1]	298 ^[2]		
Units: Percentage of participants				
number (not applicable)	41.6	48.7		

Notes:

[1] - mITT Population

[2] - mITT Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo (DB Phase) v Belimumab 10 mg/kg (DB Phase)
Number of subjects included in analysis	447
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1068
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.93
upper limit	2.11

Primary: Percentage of participants achieving a SRI response rate with the modified SLEDAI-2K scoring for proteinuria at Week 24 of OL Phase

End point title	Percentage of participants achieving a SRI response rate with the modified SLEDAI-2K scoring for proteinuria at Week 24 of OL Phase ^[3]
-----------------	--

End point description:

SRI response is defined as ≥ 4 point reduction, from OL Baseline in SS score (with the modified SLEDAI-2K scoring for PU), no worsening (increase of < 0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. mITT OL population comprised of Intent-to-Treat (ITT) OL population (all randomized participants who received at least one dose of OL treatment) excluding participants who had any assessment at 3 sites (202196, 202513 or 107286). For participants switching from placebo to belimumab 10 mg/kg IV in the open-label phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the open-label phase, Baseline was defined as Day 1 of the double-blind phase. Only those participants with data available at the specified data points were analyzed.

End point type	Primary
End point timeframe:	
Week 24 of OL phase (Week 76)	
Notes:	
[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: There are no statistical data to report.	

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	69 ^[4]	208 ^[5]		
Units: Percentage of participants				
number (not applicable)	18.8	73.6		

Notes:

[4] - mITT OL Population

[5] - mITT OL Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with non-serious adverse events (nSAEs) and serious adverse events (SAEs) [OL Phase]

End point title	Number of participants with non-serious adverse events (nSAEs) and serious adverse events (SAEs) [OL Phase] ^[6]
-----------------	--

End point description:

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Number of participants who had common nSAEs ($\geq 5\%$) and any SAEs are presented. Intent-to-Treat (ITT) OL Population comprised of all randomized participants who received at least one dose of open label treatment. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

End point type	Primary
End point timeframe:	
Week 52 to Week 84	
Notes:	
[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.	
Justification: There are no statistical data to report.	

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	117 ^[7]	242 ^[8]		
Units: Participants				
nSAEs	23	49		
SAEs	6	13		

Notes:

[7] - Intent-to-Treat (ITT) OL Population

[8] - Intent-to-Treat (ITT) OL Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with severe AEs [OL Phase]

End point title	Number of participants with severe AEs [OL Phase] ^[9]
-----------------	--

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

End point type	Primary
----------------	---------

End point timeframe:

Week 52 to Week 84

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	117 ^[10]	242 ^[11]		
Units: Participants	10	9		

Notes:

[10] - ITT OL Population

[11] - ITT OL Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with AEs leading to treatment discontinuation [OL Phase]

End point title	Number of participants with AEs leading to treatment discontinuation [OL Phase] ^[12]
-----------------	---

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

End point type	Primary
----------------	---------

End point timeframe:

Week 52 to Week 84

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	117 ^[13]	242 ^[14]		
Units: Participants	1	0		

Notes:

[13] - ITT OL Population

[14] - ITT OL Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with worst toxicity Grade 3 or 4 for hematology parameters [OL Phase]

End point title	Number of participants with worst toxicity Grade 3 or 4 for hematology parameters [OL Phase] ^[15]
-----------------	--

End point description:

Blood samples were collected for the assessment of hematology parameters. The parameters assessed were activated partial thromboplastin time (APTT), hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to Division of Microbiology and Infectious Diseases (DMID [Modified from DMID Adult Toxicity Tables, 2001]) AE Severity Grading. Number of participants with worst toxicity Grade 3 or 4 for hematology parameters have been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

End point type	Primary
----------------	---------

End point timeframe:

Week 52 to Week 84

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	115 ^[16]	235 ^[17]		
Units: Participants				
APTT, Grade 3, n=93,203	0	1		
APTT, Grade 4, n=93,203	0	0		
Hemoglobin, Grade 3, n=115,235	4	6		
Hemoglobin, Grade 4, n=115,235	0	0		
Leukocytes, Grade 3, n=114,235	0	6		
Leukocytes, Grade 4, n=114,235	0	0		
Neutrophils, Grade 3, n=114,234	2	6		

Neutrophils, Grade 4, n=114,234	0	1		
Platelets, Grade 3, n=115,235	0	0		
Platelets, Grade 4, n=115,235	0	0		
Prothrombin time, Grade 3, n=93, 204	3	2		
Prothrombin time, Grade 4, n=93, 204	1	3		

Notes:

[16] - ITT OL Population

[17] - ITT OL Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with worst toxicity Grade of 3 or 4 for clinical chemistry parameters [OL Phase]

End point title	Number of participants with worst toxicity Grade of 3 or 4 for clinical chemistry parameters [OL Phase] ^[18]
-----------------	---

End point description:

Blood samples were collected for the assessment of liver function and other chemistry parameters. The parameters assessed were alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyl transferase (GGT), bilirubin, albumin, creatinine, hyperglycemia, hypoglycemia and urate. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for liver function and other chemistry parameters have been presented. Only those participants with data available at the specified data points were analyzed. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

End point type	Primary
----------------	---------

End point timeframe:

Week 52 to Week 84

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	115 ^[19]	236 ^[20]		
Units: Participants				
ALP, Grade 3	0	0		
ALP, Grade 4	0	0		
ALT, Grade 3	0	0		
ALT, Grade 4	0	0		
AST, Grade 3	0	0		
AST, Grade 4	0	0		
Bilirubin, Grade 3	0	0		
Bilirubin, Grade 4	0	0		
GGT, Grade 3	0	1		
GGT, Grade 4	0	0		
Albumin, Grade 3	0	2		
Albumin, Grade 4	1	0		
Creatinine, Grade 3	0	0		

Creatinine, Grade 4	0	0		
Hypoglycemia, Grade 3	0	0		
Hypoglycemia, Grade 4	0	0		
Hyperglycemia, Grade 3	1	4		
Hyperglycemia, Grade 4	0	0		
Urate, Grade 3	0	0		
Urate, Grade 4	0	0		

Notes:

[19] - ITT OL Population

[20] - ITT OL Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with worst toxicity Grade of 3 or 4 for urinalysis parameters [OL Phase]

End point title	Number of participants with worst toxicity Grade of 3 or 4 for urinalysis parameters [OL Phase] ^[21]
-----------------	---

End point description:

Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life-threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

End point type	Primary
----------------	---------

End point timeframe:

Week 52 to Week 84

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	115 ^[22]	234 ^[23]		
Units: Participants				
Protein, Grade 3, n=115, 234	0	0		
Protein, Grade 4, n=115,234	0	0		
Protein/Creatinine, Grade 3,n=112,227	5	5		
Protein/Creatinine, Grade 4, n=112,227	3	0		

Notes:

[22] - ITT OL Population

[23] - ITT OL Population

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with worst toxicity Grade of 3 or 4 of

immunoglobulins [OL Phase]

End point title	Number of participants with worst toxicity Grade of 3 or 4 of immunoglobulins [OL Phase] ^[24]
-----------------	--

End point description:

Serum samples were obtained for the measurement of immunoglobulin G. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening (Grade 4) according to DMID AE Severity Grading. Number of participants with worst toxicity grade of 3 or 4 of immunoglobulin G have been presented. Only those participants with data available at the specified data points were analyzed. For Safety, participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

End point type	Primary
----------------	---------

End point timeframe:

Week 52 to Week 84

Notes:

[24] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	117 ^[25]	239 ^[26]		
Units: Participants				
Grade 3	0	1		
Grade 4	0	0		

Notes:

[25] - ITT OL Population

[26] - ITT OL Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants achieving SRI-SS Response Rate at Week 52 [DB Phase]

End point title	Percentage of participants achieving SRI-SS Response Rate at Week 52 [DB Phase]
-----------------	---

End point description:

SRI is defined as ≥ 4 point reduction, from Baseline in SS score, no worsening (increase of < 0.30 points from Baseline) in PGA and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with Baseline. Drop-outs and Treatment failures were set to non-responders. Analysis was performed using a logistic regression model for the comparison between belimumab and placebo with covariates treatment group, Baseline SS score (≤ 9 vs. ≥ 10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World). One participant in the mITT population Belimumab 10 mg/kg arm did not have a screening or Baseline PGA assessment; therefore, this participant did not contribute to the SRI/component analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 52

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	149 ^[27]	298 ^[28]		
Units: Percentage of participants				
number (not applicable)	41.6	49.0		

Notes:

[27] - mITT Population

[28] - mITT Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo (DB Phase) v Belimumab 10 mg/kg (DB Phase)
Number of subjects included in analysis	447
Analysis specification	Pre-specified
Analysis type	superiority ^[29]
P-value	= 0.0937
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.94
upper limit	2.15

Notes:

[29] - Nominal p-value due to step-down sequential testing procedure.

Secondary: Percentage of participants achieving SRI-SS Response Rate with the SELENA SLEDAI for scoring of proteinuria at Week 24 of OL Phase

End point title	Percentage of participants achieving SRI-SS Response Rate with the SELENA SLEDAI for scoring of proteinuria at Week 24 of OL Phase
-----------------	--

End point description:

SRI response is defined as ≥ 4 point reduction, from OL Baseline in SS scoring for PU, no worsening (increase of < 0.30 points from OL Baseline) in PGA and no new BILAG A ODS or 2 new BILAG B ODS compared with OL Baseline. For participants switching from placebo to belimumab 10 mg/kg IV in the open-label phase, Baseline was defined as the last assessment at the end of the double-blind phase (i.e. Week 52) pre-OL treatment. For participants that received belimumab 10 mg/kg IV during the double-blind phase and continued to receive belimumab 10 mg/kg IV during the open-label phase, Baseline was defined as Day 1 of the double-blind phase. Only those participants with data available at the specified data points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 24 of OL phase (Week 76)

End point values	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)	Placebo to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	208 ^[30]	67 ^[31]		
Units: Percentage of participants				
number (not applicable)	73.1	19.4		

Notes:

[30] - mITT OL Population

[31] - mITT OL Population

Statistical analyses

No statistical analyses for this end point

Secondary: Time to first severe flare (as measured by the modified SLE Flare Index) up to 52 Weeks [DB Phase]

End point title	Time to first severe flare (as measured by the modified SLE Flare Index) up to 52 Weeks [DB Phase]
-----------------	--

End point description:

Time to first severe SLE flare is defined as the number of days from treatment start date until the participant met an event (event date – treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes severe flares (SF) that were triggered only by an increase in SS score to >12 (this may only represent a modest increase in disease activity). Treatment failures were imputed as SF. Only post-Baseline SF were considered. Analysis was performed using Cox proportional hazards model for the comparison between belimumab and placebo adjusting for Baseline SS-S2K score (<=9 vs. >=10), baseline complement levels (at least 1 C3/C4 low vs. no C3/C4 low), and region (US/Canada vs. Rest of World). Median and inter-Quartile range (1st and 3rd Quartiles) have been presented. 99999 indicated data was not available because the number of events was too low to estimate the value.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 52 Weeks

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	149 ^[32]	299 ^[33]		
Units: Days				
median (inter-quartile range (Q1-Q3))	99999 (346 to 99999)	99999 (99999 to 99999)		

Notes:

[32] - mITT Population

[33] - mITT Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo (DB Phase) v Belimumab 10 mg/kg (DB Phase)

Number of subjects included in analysis	448
Analysis specification	Pre-specified
Analysis type	superiority ^[34]
P-value	= 0.2264
Method	Cox proportional hazards model
Parameter estimate	Hazard ratio (HR)
Point estimate	0.77
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.51
upper limit	1.17

Notes:

[34] - Nominal p-value due to step-down sequential testing procedure.

Secondary: Time to first severe flare (as measured by the modified SLE Flare Index) [OL Phase]

End point title	Time to first severe flare (as measured by the modified SLE Flare Index) [OL Phase]
-----------------	---

End point description:

Time to first severe SLE flare is defined as the number of days from OL treatment start date until the participant met an event (event date – OL treatment start date +1). Analyses of severe SLE flare was performed on modified SS SLE flare index that excludes SF that were triggered only by an increase in SS score to >12. For participants who died, data were censored at date of death if no SF occurred before death. Only post first OL treatment SF were considered. Median and inter-Quartile range (25th and 75th percentile) have been presented. 99999 indicated data was not available because the number of events was too low to estimate the value.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 24 of OL Phase (Week 76)

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	109 ^[35]	225 ^[36]		
Units: Days				
median (inter-quartile range (Q1-Q3))	99999 (99999 to 99999)	232 (232 to 99999)		

Notes:

[35] - mITT OL Population

[36] - mITT OL Population

Statistical analyses

No statistical analyses for this end point

Secondary: Percent of participants whose average prednisone dose had been reduced by >=25% from Baseline to <=7.5 mg/Day during Week 40 through 52, in participants receiving greater than 7.5 mg/Day at Baseline [DB Phase]

End point title	Percent of participants whose average prednisone dose had been reduced by $\geq 25\%$ from Baseline to ≤ 7.5 mg/Day during Week 40 through 52, in participants receiving greater than 7.5 mg/Day at Baseline [DB Phase]
End point description:	
Average (avg.) daily prednisone (PRED.) dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both Systemic Lupus Erythema (SLE) and non-SLE reasons. A responder was defined as having a PRED. reduction [REDN.] by $\geq 25\%$ from Baseline to ≤ 7.5 mg/day during Weeks 40 through 52. At Baseline, the avg. daily prednisone dose [PD] was the sum of all PDs over 7 consecutive days [excluding Day 0], divided (DIV.) by 7. For analysis, the avg. PD was the total PD during Weeks 40 through 52 DIV. by the number of days during Weeks 40 through 52. Analysis was performed using a logistic regression model with covariates treatment group, Baseline PD, Baseline SS-S2K score, (≤ 9 vs ≥ 10), Baseline complement levels (low C3 and/or C4 vs. no low C3 or C4) and region (US/Canada vs. Rest of World). Only those participants with Baseline prednisone dose > 7.5 mg/day were included.	
End point type	Secondary
End point timeframe:	
Baseline and Week 40 through Week 52	

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	95 ^[37]	184 ^[38]		
Units: Percentage of participants				
number (not applicable)	12.6	14.7		

Notes:

[37] - mITT Population

[38] - mITT Population

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo (DB Phase) v Belimumab 10 mg/kg (DB Phase)
Number of subjects included in analysis	279
Analysis specification	Pre-specified
Analysis type	superiority ^[39]
P-value	= 0.4996
Method	Regression, Logistic
Parameter estimate	Odds ratio (OR)
Point estimate	1.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.61
upper limit	2.8

Notes:

[39] - Nominal p-value due to step-down sequential testing procedure.

Secondary: Percent of participants whose average prednisone dose had been reduced to ≤ 7.5 mg/Day in participants receiving greater than 7.5 mg/Day at pre-belimumab Baseline (at Week 28 of OL Phase)

End point title	Percent of participants whose average prednisone dose had
-----------------	---

been reduced to ≤ 7.5 mg/Day in participants receiving greater than 7.5 mg/Day at pre-belimumab Baseline (at Week 28 of OL Phase)

End point description:

Average daily prednisone dose was calculated taking into account all steroids taken intravenously, intramuscularly, subcutaneously, intradermally and orally for both SLE and non-SLE reasons. A responder was defined as a participant who decreased their daily prednisone dose to ≤ 7.5 mg/day from an OL Baseline dose > 7.5 mg/day. The OL Baseline was defined as the last available value prior to the initiation of treatment with belimumab. The average daily prednisone dose was the sum of all PDs over 7 consecutive days including OL Week 28 divided by 7. Only those participants with data available at the specified data points were analyzed.

End point type Secondary

End point timeframe:

OL Baseline and Week 28 of OL Phase (Week 80)

End point values	Placebo to Belimumab 10 mg/kg (OL Phase)	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	54 ^[40]	138 ^[41]		
Units: Percentage of participants				
number (not applicable)	14.8	31.9		

Notes:

[40] - mITT OL Population

[41] - mITT OL Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with nSAEs and SAEs [DB Phase]

End point title Number of participants with nSAEs and SAEs [DB Phase]

End point description:

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, other situations judged by physician, is associated with liver injury and impaired liver function. Safety population was defined as all participants who were randomized and treated with at least one dose of study treatment. Number of participants who had common nSAEs ($\geq 5\%$) and any SAEs are presented.

End point type Secondary

End point timeframe:

Up to 52 Weeks

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	165 ^[42]	331 ^[43]		
Units: Participants				
nSAEs	77	196		
SAEs	31	36		

Notes:

[42] - Safety Population

[43] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with severe AEs [DB Phase]

End point title	Number of participants with severe AEs [DB Phase]
End point description: An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with severe AEs have been presented.	
End point type	Secondary
End point timeframe: Up to 52 Weeks	

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	165 ^[44]	331 ^[45]		
Units: Participants	37	46		

Notes:

[44] - Safety Population

[45] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with AEs leading to treatment discontinuation [DB Phase]

End point title	Number of participants with AEs leading to treatment discontinuation [DB Phase]
End point description: An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants with AEs leading to treatment discontinuation have been presented.	
End point type	Secondary
End point timeframe: Up to 52 Weeks	

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	165 ^[46]	331 ^[47]		
Units: Participants	12	22		

Notes:

[46] - Safety Population

[47] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with worst toxicity Grade 3 or 4 for hematology parameters [DB Phase]

End point title	Number of participants with worst toxicity Grade 3 or 4 for hematology parameters [DB Phase]
-----------------	--

End point description:

Blood samples were collected for the assessment of hematology parameters up to 52 Weeks. The parameters assessed were APTT, hemoglobin, leukocytes, neutrophils, platelets and prothrombin time. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Number of participants with worst toxicity Grade of 3 or 4 for hematology parameters have been presented. Only those participants with data available at specified time points were analyzed (represented by n=x in the category titles).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 52 weeks

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161 ^[48]	327 ^[49]		
Units: Participants				
APTT, Grade 3, n=159,318	0	3		
APTT, Grade 4, n=159,318	0	2		
Hemoglobin, Grade 3, n=161,327	5	15		
Hemoglobin, Grade 4, n=161,327	1	0		
Leukocytes, Grade 3, n=161,327	3	17		
Leukocytes, Grade 4, n=161,327	1	0		
Neutrophils, Grade 3, n=161,327	9	28		
Neutrophils, Grade 4, n=161,327	1	5		
Platelets, Grade 3, n=161,327	1	1		
Platelets, Grade 4, n=161,327	0	1		
Prothrombin time, Grade 3, n=159, 318	8	10		
Prothrombin time, Grade 4, n=159,318	2	6		

Notes:

[48] - Safety Population

[49] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with worst toxicity Grade of 3 or 4 for clinical chemistry parameters [DB Phase]

End point title	Number of participants with worst toxicity Grade of 3 or 4 for clinical chemistry parameters [DB Phase]
-----------------	---

End point description:

Blood samples were collected for the assessment of liver function and other chemistry parameters up to 52 Weeks. The parameters assessed were ALT, AST, GGT, albumin, hyperglycemia and hypoglycemia. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity Grade of 3 or 4 for other chemistry parameters have been presented. Only those participants with data available at the specified data points were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to 52 weeks

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161 ^[50]	327 ^[51]		
Units: Participants				
ALT, Grade 3	0	2		
AST, Grade 3	0	2		
GGT, Grade 3	6	6		
GGT, Grade 4	0	1		
Albumin, Grade 3	5	3		
Albumin, Grade 4	1	1		
Hyperglycemia, Grade 3	4	7		
Hyperglycemia, Grade 4	1	1		
Hypoglycemia, Grade 3	0	4		
Hypoglycemia, Grade 4	3	1		

Notes:

[50] - Safety Population

[51] - Safety Population

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with worst toxicity Grade of 3 or 4 for urinalysis parameters [DB Phase]

End point title	Number of participants with worst toxicity Grade of 3 or 4 for urinalysis parameters [DB Phase]
End point description:	
Urinalysis parameters assessed were urine protein and protein/creatinine. Urine samples were collected for the measurement of urinalysis parameters by dipstick method up to 52 Weeks. Grading was assigned as mild (Grade 1), moderate (grade 2), severe (Grade 3) and potentially life threatening according to DMID AE Severity Grading. Only those participants with worst toxicity grade of 3 or 4 for urinalysis parameters have been presented. Only those participants with data available at specified time points were analyzed (represented by n=x in the category titles).	
End point type	Secondary
End point timeframe:	
Up to 52 weeks	

End point values	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	161 ^[52]	324 ^[53]		
Units: Participants				
Protein, Grade 3, n=161, 324	0	1		
Protein/creatinine, Grade 3, n=161,322	8	25		
Protein/creatinine, Grade 4, n=161,322	12	11		

Notes:

[52] - Safety Population

[53] - Safety Population

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

nSAEs and SAEs were collected from the start of study treatment up to Week 52 for Double Blind phase and from Week 52 to Week 84 for OL phase. Participants that completed DB and OL phase, an additional 8 weeks follow-up was conducted (Week 84).

Adverse event reporting additional description:

nSAEs and SAEs were reported for the Safety Population which comprised of all randomized participants who received at least 1 dose of study treatment for Double Blind phase and ITT OL Population which comprised of all randomized participants who received at least 1 dose of OL treatment for OL phase.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	21.1

Reporting groups

Reporting group title	Placebo (DB Phase)
-----------------------	--------------------

Reporting group description:

In DB phase, participants received matching placebo to belimumab administered as IV infusion plus standard of care through 52 weeks.

Reporting group title	Belimumab 10 mg/kg (DB Phase)
-----------------------	-------------------------------

Reporting group description:

In DB phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care through 52 weeks.

Reporting group title	Placebo to Belimumab 10 mg/kg (OL Phase)
-----------------------	--

Reporting group description:

n OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76

Reporting group title	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)
-----------------------	---

Reporting group description:

n OL phase, participants received belimumab 10 mg/kg administered as IV infusion plus standard of care every 28 days from Week 52 through Week 76

Serious adverse events	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)	Placebo to Belimumab 10 mg/kg (OL Phase)
Total subjects affected by serious adverse events			
subjects affected / exposed	31 / 165 (18.79%)	36 / 331 (10.88%)	6 / 117 (5.13%)
number of deaths (all causes)	0	2	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Squamous cell carcinoma of the cervix			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			

Haematoma			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus vasculitis			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant hypertension			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Orthostatic hypotension			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Raynaud's phenomenon			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vasculitis			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	1 / 165 (0.61%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Ectopic pregnancy			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 165 (0.00%)	2 / 331 (0.60%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 165 (0.61%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chest pain			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Serositis			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue inflammation			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 165 (0.61%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 165 (0.00%)	2 / 331 (0.60%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus pneumonitis			
subjects affected / exposed	1 / 165 (0.61%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleurisy			
subjects affected / exposed	0 / 165 (0.00%)	2 / 331 (0.60%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung consolidation			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lupus pleurisy			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression suicidal			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Insomnia			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Joint injury			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary contusion			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Pericarditis			
subjects affected / exposed	3 / 165 (1.82%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Acute myocardial infarction			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	1 / 117 (0.85%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	1 / 117 (0.85%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiomyopathy			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tachycardia			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	1 / 117 (0.85%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coma			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dystonia			

subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Idiopathic intracranial hypertension			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Radiculopathy			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
syncope			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	1 / 117 (0.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chorea			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiparesis			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	1 / 117 (0.85%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			

subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Idiopathic orbital inflammation			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal obstruction			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pancreatitis acute			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal perforation			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Butterfly rash			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic lupus erythematosus rash			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Lupus nephritis			
subjects affected / exposed	2 / 165 (1.21%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute kidney injury			

subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Azotaemia			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Glomerulonephritis			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrotic syndrome			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Proteinuria			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal failure			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary retention			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Systemic lupus erythematosus			
subjects affected / exposed	1 / 165 (0.61%)	3 / 331 (0.91%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 4	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SLE arthritis			

subjects affected / exposed	1 / 165 (0.61%)	2 / 331 (0.60%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Costochondritis			
subjects affected / exposed	0 / 165 (0.00%)	2 / 331 (0.60%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscular weakness			
subjects affected / exposed	0 / 165 (0.00%)	2 / 331 (0.60%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibromyalgia			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal chest pain			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			

subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rhabdomyolysis			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tendonitis			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	1 / 117 (0.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	6 / 165 (3.64%)	2 / 331 (0.60%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	4 / 6	1 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cellulitis			
subjects affected / exposed	1 / 165 (0.61%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	2 / 165 (1.21%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Amoebic colitis			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis gonococcal			

subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile infection			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Paronychia			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral tonsillitis			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	0 / 165 (0.00%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperkalaemia			

subjects affected / exposed	0 / 165 (0.00%)	1 / 331 (0.30%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoalbuminaemia			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoglycaemia			
subjects affected / exposed	1 / 165 (0.61%)	0 / 331 (0.00%)	0 / 117 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Total subjects affected by serious adverse events			
subjects affected / exposed	13 / 242 (5.37%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Squamous cell carcinoma of the cervix			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lupus vasculitis			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant hypertension			

subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Orthostatic hypotension			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Raynaud's phenomenon			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vasculitis			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertension			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ectopic pregnancy			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Non-cardiac chest pain			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Pyrexia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chest pain			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fatigue			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Serositis			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Soft tissue inflammation			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Oedema			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dyspnoea			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		

Lupus pneumonitis			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pleurisy			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lung consolidation			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lupus pleurisy			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Depression suicidal			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Insomnia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Suicidal ideation			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural			

complications				
Accidental overdose				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Joint injury				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pelvic fracture				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary contusion				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wrist fracture				
subjects affected / exposed	1 / 242 (0.41%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cardiac disorders				
Pericarditis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Acute myocardial infarction				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrial fibrillation				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Cardiomyopathy			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ventricular tachycardia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Coma			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dystonia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Idiopathic intracranial hypertension			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Radiculopathy			

subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
syncope			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chorea			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Hemiparesis			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukopenia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			

Idiopathic orbital inflammation subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 242 (0.00%) 0 / 0 0 / 0		
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 242 (0.00%) 0 / 0 0 / 0		
Colitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 242 (0.00%) 0 / 0 0 / 0		
Diarrhoea subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 242 (0.00%) 0 / 0 0 / 0		
Enteritis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 242 (0.00%) 0 / 0 0 / 0		
Intestinal obstruction subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 242 (0.00%) 0 / 0 0 / 0		
Pancreatitis acute subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 242 (0.00%) 0 / 0 0 / 0		
Small intestinal perforation subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 242 (0.00%) 0 / 0 0 / 0		
Hepatobiliary disorders			

Cholecystitis			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Butterfly rash			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Systemic lupus erythematosus rash			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Lupus nephritis			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Acute kidney injury			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Azotaemia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Glomerulonephritis			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Nephrotic syndrome			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Proteinuria			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal failure			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary retention			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Systemic lupus erythematosus			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
SLE arthritis			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Costochondritis			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Muscular weakness			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Arthritis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Fibromyalgia				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal chest pain				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Musculoskeletal pain				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myositis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteoarthritis				
subjects affected / exposed	1 / 242 (0.41%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Rhabdomyolysis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tendonitis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				

Pneumonia				
subjects affected / exposed	2 / 242 (0.83%)			
occurrences causally related to treatment / all	1 / 2			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Urinary tract infection				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Amoebic colitis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Appendicitis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arthritis gonococcal				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atypical pneumonia				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile infection				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dengue fever				

subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung infection				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Meningitis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Paronychia				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Staphylococcal sepsis				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Upper respiratory tract infection				
subjects affected / exposed	0 / 242 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Viral tonsillitis				

subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Oesophageal candidiasis			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Soft tissue infection			
subjects affected / exposed	1 / 242 (0.41%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperkalaemia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoalbuminaemia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoglycaemia			
subjects affected / exposed	0 / 242 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo (DB Phase)	Belimumab 10 mg/kg (DB Phase)	Placebo to Belimumab 10 mg/kg (OL Phase)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	77 / 165 (46.67%)	196 / 331 (59.21%)	23 / 117 (19.66%)
Vascular disorders			
Hypertension			
subjects affected / exposed	4 / 165 (2.42%)	18 / 331 (5.44%)	0 / 117 (0.00%)
occurrences (all)	5	21	0
Nervous system disorders			
Headache			
subjects affected / exposed	18 / 165 (10.91%)	39 / 331 (11.78%)	0 / 117 (0.00%)
occurrences (all)	25	47	0
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	9 / 165 (5.45%)	31 / 331 (9.37%)	0 / 117 (0.00%)
occurrences (all)	12	34	0
Nausea			
subjects affected / exposed	15 / 165 (9.09%)	18 / 331 (5.44%)	0 / 117 (0.00%)
occurrences (all)	21	29	0
Vomiting			
subjects affected / exposed	7 / 165 (4.24%)	19 / 331 (5.74%)	0 / 117 (0.00%)
occurrences (all)	8	21	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	7 / 165 (4.24%)	18 / 331 (5.44%)	0 / 117 (0.00%)
occurrences (all)	7	23	0
Psychiatric disorders			
Insomnia			
subjects affected / exposed	10 / 165 (6.06%)	18 / 331 (5.44%)	0 / 117 (0.00%)
occurrences (all)	10	18	0
Depression			
subjects affected / exposed	9 / 165 (5.45%)	15 / 331 (4.53%)	0 / 117 (0.00%)
occurrences (all)	9	15	0
Musculoskeletal and connective tissue disorders			

Back pain subjects affected / exposed occurrences (all)	10 / 165 (6.06%) 12	16 / 331 (4.83%) 17	7 / 117 (5.98%) 7
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	14 / 165 (8.48%) 20	48 / 331 (14.50%) 58	4 / 117 (3.42%) 6
Urinary tract infection subjects affected / exposed occurrences (all)	19 / 165 (11.52%) 24	43 / 331 (12.99%) 57	7 / 117 (5.98%) 7
Influenza subjects affected / exposed occurrences (all)	17 / 165 (10.30%) 23	28 / 331 (8.46%) 35	7 / 117 (5.98%) 8
Sinusitis subjects affected / exposed occurrences (all)	9 / 165 (5.45%) 9	26 / 331 (7.85%) 33	0 / 117 (0.00%) 0

Non-serious adverse events	Belimumab 10 mg/kg to Belimumab 10 mg/kg (OL Phase)		
Total subjects affected by non-serious adverse events subjects affected / exposed	49 / 242 (20.25%)		
Vascular disorders Hypertension subjects affected / exposed occurrences (all)	0 / 242 (0.00%) 0		
Nervous system disorders Headache subjects affected / exposed occurrences (all)	0 / 242 (0.00%) 0		
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Vomiting	0 / 242 (0.00%) 0 0 / 242 (0.00%) 0		

subjects affected / exposed occurrences (all)	0 / 242 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	0 / 242 (0.00%) 0		
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) Depression subjects affected / exposed occurrences (all)	0 / 242 (0.00%) 0 0 / 242 (0.00%) 0		
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	3 / 242 (1.24%) 3		
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all) Urinary tract infection subjects affected / exposed occurrences (all) Influenza subjects affected / exposed occurrences (all) Sinusitis subjects affected / exposed occurrences (all)	20 / 242 (8.26%) 21 13 / 242 (5.37%) 15 16 / 242 (6.61%) 18 0 / 242 (0.00%) 0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 June 2012	Revisions to inclusion criterion (contraception for female participants), requiring clinical supervision for 3 hours after participants received their first 2 infusions, and removing the provision to withdraw participants from the study if 3 or more consecutive doses of investigational product were missed. Additional changes included clarifying timing of several evaluations and doses and clarifying timing of the evaluations and dosing in the 6-month open-label phase.
09 February 2017	Revising the primary endpoint to the SRI-S2K, reducing the sample size, adding the provision to withdraw participants from the study if 3 or more consecutive doses of investigational product were missed, and modifying the enrollment criteria. Additional changes include aligning the safety sections with the belimumab program standard text and clarifying conduct sections.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported